retinitis pigmentosa (RP)

Reactivating cones possibility in addressing RPGlucose entrapment in the retinal pigment epithelium is responsible for central vision loss in retinitis pigmentosa. Injecting wild-type rods into the eye to restore glucose transportation or injecting glucose into the subretinal space can facilitate cone regeneration.
Neuroprotective strategy primed for progress
Neuroprotective strategy primed for progressAdvancing methods for evaluating therapeutic response have fostered a new era in glaucoma neuroprotection in which promising candidates are already being investigated in clinical trials and others are poised to begin phase I testing, said Jeffrey L. Goldberg, MD, PhD.
Gene therapy trial launched for X-linked retinitis pigmentosaResearchers have injected their first patient with a virus engineered to remodel the gene responsible for X-linked retinitis pigmentosa (XLRP).
Transplantable 3-D retinas
Transplantable 3-D retinasAIVITA Biomedical has successfully engineered a three-dimensional transplantable retina construct and demonstrated connectivity and conductivity in an animal model of retinal degeneration.
New mosaic retinitis pigmentosa mutation reportedInvestigators in Israel have discovered a retinitis pigmentosa-causing mutation for which unaffected individuals can be mosaic, followed by autosomal dominant inheritance in successive generations.
DRCR.net retinal treatment results take center stage in 2015Studies of the efficacy of anti-vascular endothelial growth factor (VEGF), gene therapies, and slow-release drug delivery systems took center stage among treatments for retinal disorders in 2015. In addition to studies already under way, others are about to begin.
Gene therapy new frontier for ocular disorders
Gene therapy new frontier for ocular disordersThe advent of gene therapy poses a new area of drug development for inherited and acquires ocular disorders.